• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

InCl 介导的吲哚及其衍生物的杂芳基化反应:通过 CH 活化策略发现 2-(1H-吲哚-3-基)-喹喔啉衍生物作为一类新的 PDE4B 选择性抑制剂用于关节炎和/或多发性硬化症。

InCl mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.

机构信息

Dr. Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India.

Dr. Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India; Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Madhav Nagar, 576 104, Karnataka, India.

出版信息

Eur J Med Chem. 2019 Jul 15;174:198-215. doi: 10.1016/j.ejmech.2019.04.020. Epub 2019 Apr 16.

DOI:10.1016/j.ejmech.2019.04.020
PMID:31035240
Abstract

A new class of PDE4 inhibitors were designed and synthesized via the InCl mediated heteroarylation of indoles and their further derivatization through the Pd(II)-catalyzed CH activation strategy. This effort allowed us to discover a series of 2-(1H-indol-3-yl)-quinoxaline based inhibitors possessing PDE4B selectivity over PDE4D and PDE4C. One of these compounds i.e. 3b (PDE4B IC = 0.39 ± 0.13 μM with ∼27 and > 250 fold selectivity for PDE4B over PDE4D and C, respectively) showed effects in Zebrafish experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis when dosed at 3, 10 and 30 mg/kg intraperitoneally. Indeed, it halted the progression of the disease across all these doses tested. At an intraperitoneal dose of 30 mg/kg the compound 3b showed promising effects in adjuvant induced arthritic rats. The compound reduced paw volume, inflammation and pannus formation (in the knee joints) as well as pro-inflammatory gene expression/mRNA levels significantly in arthritic rats. Moreover, this compound was found to be selective towards PDE4 over other families of PDEs in vitro and safe when tested for its probable toxicity (e.g. teratogenicity, hepatotoxicity and cardiotoxicity) in Zebrafish.

摘要

我们通过 InCl 介导的吲哚杂芳基化及其钯(II)催化的 CH 活化策略,设计并合成了一类新型的 PDE4 抑制剂。通过这种方法,我们发现了一系列基于 2-(1H-吲哚-3-基)-喹喔啉的抑制剂,对 PDE4B 具有选择性,对 PDE4D 和 PDE4C 的选择性超过 27 倍和>250 倍。其中一种化合物,即 3b(PDE4B IC=0.39±0.13μM,对 PDE4D 和 C 的选择性分别约为 27 倍和>250 倍),在多发性硬化症的斑马鱼实验性自身免疫性脑脊髓炎(EAE)模型中,当以 3、10 和 30mg/kg 的剂量腹腔内给药时,显示出疗效。事实上,它阻止了所有测试剂量下疾病的进展。在 30mg/kg 的腹腔内剂量下,该化合物 3b 在佐剂诱导的关节炎大鼠中显示出良好的疗效。该化合物可显著减少关节炎大鼠的足爪体积、炎症和血管翳形成(膝关节)以及促炎基因表达/mRNA 水平。此外,该化合物在体外对 PDE4 具有选择性,且在斑马鱼中测试其可能的毒性(例如致畸性、肝毒性和心脏毒性)时是安全的。

相似文献

1
InCl mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.InCl 介导的吲哚及其衍生物的杂芳基化反应:通过 CH 活化策略发现 2-(1H-吲哚-3-基)-喹喔啉衍生物作为一类新的 PDE4B 选择性抑制剂用于关节炎和/或多发性硬化症。
Eur J Med Chem. 2019 Jul 15;174:198-215. doi: 10.1016/j.ejmech.2019.04.020. Epub 2019 Apr 16.
2
Targeting next-generation PDE4 inhibitors in search of potential management of rheumatoid arthritis and psoriasis.靶向新一代 PDE4 抑制剂,探寻类风湿性关节炎和银屑病的潜在治疗方法。
Bioorg Chem. 2024 Oct;151:107689. doi: 10.1016/j.bioorg.2024.107689. Epub 2024 Aug 2.
3
PdCl-catalyzed synthesis of a new class of isocoumarin derivatives containing aminosulfonyl / aminocarboxamide moiety: First identification of a isocoumarin based PDE4 inhibitor.PdCl 催化合成含氨基磺酰基/氨基甲酰基部分的新型异噁唑啉衍生物:首个基于异噁唑啉的 PDE4 抑制剂的鉴定。
Eur J Med Chem. 2021 Oct 5;221:113514. doi: 10.1016/j.ejmech.2021.113514. Epub 2021 May 6.
4
Fe(III)-catalyzed regioselective and faster synthesis of isocoumarins with 3-oxoalkyl moiety at C-4: Identification of new inhibitors of PDE4.Fe(III)催化的具有 3-氧代烷基部分的 C-4 位区域和立体选择性的异香豆素快速合成:PDE4 的新型抑制剂的鉴定。
Bioorg Chem. 2022 Apr;121:105667. doi: 10.1016/j.bioorg.2022.105667. Epub 2022 Feb 9.
5
C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.喹啉环 C-2 上的 C-C 键形成:作为一类新型 PDE4 抑制剂的 2-(1H-吲哚-3-基)喹啉-3-甲腈衍生物的合成。
Bioorg Med Chem. 2012 Apr 1;20(7):2199-207. doi: 10.1016/j.bmc.2012.02.027. Epub 2012 Feb 16.
6
Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis.选择性磷酸二酯酶4(PDE4)亚型抑制为干预多发性硬化症的神经炎症与髓鞘损伤特征提供了新机会。
Brain Behav Immun. 2023 Mar;109:1-22. doi: 10.1016/j.bbi.2022.12.020. Epub 2022 Dec 28.
7
Novel N-indolylmethyl substituted olanzapine derivatives: their design, synthesis and evaluation as PDE4B inhibitors.新型 N-吲哚基取代的奥氮平衍生物:作为 PDE4B 抑制剂的设计、合成与评价。
Org Biomol Chem. 2013 Apr 7;11(13):2075-9. doi: 10.1039/c3ob27424a.
8
Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.设计、合成及新型儿茶酚嘧啶基 PDE4 抑制剂的生物学评价,用于治疗特应性皮炎。
Eur J Med Chem. 2018 Feb 10;145:673-690. doi: 10.1016/j.ejmech.2017.12.069. Epub 2017 Dec 19.
9
CuCl-catalyzed inexpensive, faster and ligand/additive free synthesis of isoquinolin-1(2H)-one derivatives via the coupling-cyclization strategy: Evaluation of a new class of compounds as potential PDE4 inhibitors.CuCl 催化的廉价、快速、无需配体/添加剂的异喹啉-1(2H)-酮衍生物的偶联-环化策略合成:作为潜在 PDE4 抑制剂的新型化合物的评估。
Bioorg Chem. 2021 Oct;115:105265. doi: 10.1016/j.bioorg.2021.105265. Epub 2021 Aug 13.
10
Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.作为潜在磷酸二酯酶4(PDE4)抑制剂的1,2,3,4-四氢异喹啉衍生物的基于结构的设计及构效关系
Bioorg Med Chem Lett. 2018 Apr 15;28(7):1188-1193. doi: 10.1016/j.bmcl.2018.02.056. Epub 2018 Mar 6.

引用本文的文献

1
Phosphodiesterase 4B (PDE4B) inhibitors and their applications in recent years (2014 to early 2025).磷酸二酯酶4B(PDE4B)抑制剂及其近年来(2014年至2025年初)的应用。
Mol Divers. 2025 Jun 14. doi: 10.1007/s11030-025-11242-2.
2
Phosphodiesterase 4 inhibition as a novel treatment for stroke.磷酸二酯酶4抑制作为中风的一种新疗法。
PeerJ. 2025 Jan 29;13:e18905. doi: 10.7717/peerj.18905. eCollection 2025.
3
The potential of zebrafish as drug discovery research tool in immune-mediated inflammatory disease.斑马鱼在免疫介导的炎症性疾病药物研发中的应用潜力。
Inflammopharmacology. 2024 Aug;32(4):2219-2233. doi: 10.1007/s10787-024-01511-1. Epub 2024 Jun 26.
4
Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity.全血甲基化特征与多发性硬化症的严重程度相关,并能准确分类。
Clin Epigenetics. 2022 Dec 30;14(1):194. doi: 10.1186/s13148-022-01397-2.
5
Quinazoline-Schiff base conjugates: study and ADMET predictions as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins.喹唑啉-席夫碱共轭物:作为冠状病毒(SARS-CoV-2)蛋白多靶点抑制剂的研究及ADMET预测
RSC Adv. 2020 Sep 15;10(56):34033-34045. doi: 10.1039/d0ra06424f. eCollection 2020 Sep 10.
6
Progress and prospects in copper-catalyzed C-H functionalization.铜催化C-H官能团化反应的进展与展望
RSC Adv. 2020 Sep 17;10(57):34429-34458. doi: 10.1039/d0ra06518h. eCollection 2020 Sep 16.
7
Zebrafish Models for the Safety and Therapeutic Testing of Nanoparticles with a Focus on Macrophages.以巨噬细胞为重点的纳米颗粒安全性和治疗测试的斑马鱼模型
Nanomaterials (Basel). 2021 Jul 9;11(7):1784. doi: 10.3390/nano11071784.
8
Use of Zebrafish in Drug Discovery Toxicology.斑马鱼在药物发现毒理学中的应用。
Chem Res Toxicol. 2020 Jan 21;33(1):95-118. doi: 10.1021/acs.chemrestox.9b00335. Epub 2019 Nov 16.